Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical model CSF1R dendranib (H74DS3M8) clinical candidate is orally bioavailable and designed to avoid safety concerns of other CSF1R tyrosine kinase inhibitors using Ashvattha’s proprietary hydroxyl dendrimer nanomedicine technology Reduction … Read more